Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06505967 · ClinicalTrials.gov registry record · NA
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels
A NA study of NAD+ Levels in the Blood, sponsored by Qualia Life Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06505967 is a NA study of NAD+ Levels in the Blood that is actively recruiting participants, run by Qualia Life Sciences. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06505967, a NA study of NAD+ Levels in the Blood, is actively recruiting participants, sponsored by Qualia Life Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine if Qualia NAD+ effectively increases NAD+ levels in the blood and to evaluate its safety. Researchers will compare Qualia NAD+ to a placebo (a look-alike substance that contains no active drug) to assess its efficacy in increasing NAD+ levels in the blood. Participants will: Take Qualia NAD+ or a placebo every day for 4 weeks. Undergo blood tests before and after the trial.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Qualia NAD+
Study Locations (1)
California
- Qualia Life Sciences - Carlsbad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2024-09-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06505967
The ClinicalTrials.gov registry entry for NCT06505967 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qualia Life Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NAD+ Levels in the Blood appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06505967 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06505967 about?
NCT06505967 is a clinical study titled "Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels". The goal of this clinical trial is to determine if Qualia NAD+ effectively increases NAD+ levels in the blood and to evaluate its safety. Researchers will compare Qualia NAD+ to a placebo (a look-alike substance that contains no active drug) to assess its efficacy in increasing NAD+ levels in the b...
What is the current status of trial NCT06505967?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-06-10. Estimated completion is 2024-09-09.
What conditions does trial NCT06505967 study?
This clinical trial studies the following conditions: NAD+ Levels in the Blood.
What interventions are being tested in trial NCT06505967?
The interventions under investigation include: Placebo (OTHER), Qualia NAD+ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06505967?
This trial is sponsored by Qualia Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06505967 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.